Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 255,870
  • Shares Outstanding, K 184,079
  • Annual Sales, $ 90,120 K
  • Annual Income, $ -276,060 K
  • EBIT $ -164 M
  • EBITDA $ -79 M
  • 60-Month Beta 0.61
  • Price/Sales 2.86
  • Price/Cash Flow N/A
  • Price/Book 3.23

Options Overview Details

View History
  • Implied Volatility 104.14% ( +10.88%)
  • Historical Volatility 64.45%
  • IV Percentile 41%
  • IV Rank 10.83%
  • IV High 911.67% on 01/17/24
  • IV Low 6.04% on 01/16/24
  • Put/Call Vol Ratio 0.64
  • Today's Volume 128
  • Volume Avg (30-Day) 72
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 3,778
  • Open Int (30-Day) 3,720

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.23
  • Number of Estimates 5
  • High Estimate -0.19
  • Low Estimate -0.26
  • Prior Year -0.19
  • Growth Rate Est. (year over year) -21.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1900 +15.13%
on 10/31/24
1.4900 -8.05%
on 10/18/24
+0.0900 (+7.03%)
since 10/07/24
3-Month
1.0800 +26.85%
on 09/06/24
1.4900 -8.05%
on 10/18/24
+0.1900 (+16.10%)
since 08/07/24
52-Week
0.4126 +232.04%
on 11/13/23
1.9280 -28.94%
on 05/13/24
+0.8220 (+150.00%)
since 11/07/23

Most Recent Stories

More News
Nektar: Q3 Earnings Snapshot

Nektar: Q3 Earnings Snapshot

NKTR : 1.3700 (-1.44%)
Wall Street is Overlooking This Penny Stock, Says Analyst

This penny stock could surge up to 200%, according to one bull, who has high hopes for a pipeline drug ahead of trial data due out in 2025.

AAPL : 227.48 (+2.14%)
AMZN : 210.05 (+1.43%)
NKTR : 1.3700 (-1.44%)
Nektar: Q2 Earnings Snapshot

Nektar: Q2 Earnings Snapshot

NKTR : 1.3700 (-1.44%)
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress

/PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced new data for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg)...

NKTR : 1.3700 (-1.44%)
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy

/PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will have two presentations for rezpegaldesleukin (REZPEG), a first-in-class...

NKTR : 1.3700 (-1.44%)
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it has entered into a new clinical study collaboration with Cellular Biomedicine Group...

NKTR : 1.3700 (-1.44%)
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event on Wednesday, September 13, 2023 at...

NKTR : 1.3700 (-1.44%)
Nektar Therapeutics Reports Second Quarter 2023 Financial Results

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2023. Cash and investments in...

NKTR : 1.3700 (-1.44%)
Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that efficacy data previously generated by Eli Lilly & Company for rezpegaldesleukin...

NKTR : 1.3700 (-1.44%)
Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2023 on Tuesday, August 8, 2023, after the close...

NKTR : 1.3700 (-1.44%)

Business Summary

Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration...

See More

Key Turning Points

3rd Resistance Point 1.5133
2nd Resistance Point 1.4667
1st Resistance Point 1.4183
Last Price 1.3700
1st Support Level 1.3233
2nd Support Level 1.2767
3rd Support Level 1.2283

See More

52-Week High 1.9280
Last Price 1.3700
Fibonacci 61.8% 1.3491
Fibonacci 50% 1.1703
Fibonacci 38.2% 0.9915
52-Week Low 0.4126

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar